HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Angelalign Technology (6699.HK) 22H1 - Still “Bubble” in Valuation; The Era of High Margin Is Over

Pine Care Group (1989.HK) - Hard to Make Profits Due to Industry Characteristics; Here Is What to Do

Modern Dental Group (3600.HK)- 2023 Harsh Reality Is Hard to Avoid, but Short-Term Rally Is Possible

Modern Dental Group (3600.HK) - More Suitable for Short Term Trading than Long Term Holding

Angelalign Technology (6699.HK) - Uncertain Growth Outlook

Angelalign Technology (6699.HK) - There Is Still Plenty of Downside, but Limited Upside Potential

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

<ul>
<li>Due to better-than-expected VBP results, we saw a decent rally of MDG’s share price last Friday. However, all the medical products that are covered by VBP begin to lose logic. </li>
<li>Backwardness in R&amp;D is a bottleneck restricting MDG's future growth. MDG is more like a manufacturing/processing plant relying on labor dividends than a technology company with high product added value.</li>
<li>Multiple risks (e.g.pandemic, depreciation of exchange rate against US dollar, economic downturn, etc.) will add more uncertainties to MDG's 2022 performance. MDG’s share price could remain tepid after temporary rally. </li>
</ul>


Due to better-than-expected VBP results, we saw a decent rally of MDG’s share price last Friday. However, all the medical products that are covered by VBP begin to lose logic. 
Backwardness in R&amp;D is a bottleneck restricting MDG's future growth. MDG is more like a manufacturing/processing plant relying on labor dividends than a technology company with high product added value.
Multiple risks (e.g.pandemic, depreciation of exchange rate against US dollar, economic downturn, etc.) will add more uncertainties to MDG's 2022 performance. MDG’s share price could remain tepid after temporary rally. 


Modern Dental Group (3600.HK) 22H1- Share Price May Remain Tepid Due to Lack of Core Competitiveness